Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 34: 2264-2267, 1988;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niwa, T.
Right arrow Articles by Maeda, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niwa, T.
Right arrow Articles by Maeda, K.

Clinical Chemistry, Vol 34, 2264-2267, Copyright © 1988 by American Association for Clinical Chemistry

Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography

T Niwa, N Takeda, A Tatematsu and K Maeda
Department of Internal Medicine, Nagoya University Branch Hospital, Japan.

We quantified indoxyl sulfate in uremic serum by using internal-surface reversed-phase high-performance liquid chromatography. Its concentrations were markedly increased in chronic hemodialysis patients, and were significantly but weakly correlated with the concentrations of creatinine and beta 2-microglobulin in these patients' serum, and with the duration of their hemodialysis treatment. Indoxyl sulfate could not be removed effectively by conventional hemodialysis because of its strong binding to serum albumin. Equilibrium dialysis demonstrated that indoxyl sulfate inhibited the binding of salicylate to albumin, and that 3-carboxy-4-methyl-5-propyl- 2-furanpropionic acid inhibited the binding of indoxyl sulfate to albumin. In conclusion, indoxyl sulfate was markedly accumulated in uremic serum, and inhibited drug binding.


The following articles in journals at HighWire Press have cited this article:


Home page
 CJASNHome page
F. C. Barreto, D. V. Barreto, S. Liabeuf, N. Meert, G. Glorieux, M. Temmar, G. Choukroun, R. Vanholder, Z. A. Massy, and on behalf of the European Uremic Toxin Work Group
Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients
Clin. J. Am. Soc. Nephrol., October 1, 2009; 4(10): 1551 - 1558.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Muteliefu, A. Enomoto, P. Jiang, M. Takahashi, and T. Niwa
Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells
Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2051 - 2058.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Adijiang, S. Goto, S. Uramoto, F. Nishijima, and T. Niwa
Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1892 - 1901.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. Enomoto, M. Takeda, A. Tojo, T. Sekine, S. H. Cha, S. Khamdang, F. Takayama, I. Aoyama, S. Nakamura, H. Endou, et al.
Role of Organic Anion Transporters in the Tubular Transport of Indoxyl Sulfate and the Induction of its Nephrotoxicity
J. Am. Soc. Nephrol., July 1, 2002; 13(7): 1711 - 1720.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. Miyazaki, I. Aoyama, M. Ise, H. Seo, and T. Niwa
An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-{beta}1 in uraemic rat kidneys
Nephrol. Dial. Transplant., November 1, 2000; 15(11): 1773 - 1781.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Association for Clinical Chemistry.